Emergent BioSolutions (NYSE:EBS) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a report released on Friday,Benzinga reports. The firm currently has a $15.00 target price on the biopharmaceutical company’s stock.

EBS has been the topic of a number of other reports. StockNews.com cut Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Saturday, December 28th. Rodman & Renshaw reiterated a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research report on Friday, September 13th. Finally, Benchmark upped their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Stock Down 2.2 %

NYSE:EBS opened at $9.87 on Friday. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. The stock has a 50 day moving average of $9.34 and a 200-day moving average of $9.11. The firm has a market capitalization of $534.76 million, a PE ratio of -2.41 and a beta of 1.59. Emergent BioSolutions has a 52 week low of $1.42 and a 52 week high of $15.10.

Hedge Funds Weigh In On Emergent BioSolutions

Large investors have recently bought and sold shares of the stock. B. Riley Wealth Advisors Inc. bought a new position in shares of Emergent BioSolutions during the 3rd quarter valued at about $295,000. Barclays PLC grew its position in Emergent BioSolutions by 361.6% during the third quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock valued at $329,000 after purchasing an additional 30,792 shares in the last quarter. Oak Hill Advisors LP acquired a new position in shares of Emergent BioSolutions in the third quarter worth $9,296,000. Geode Capital Management LLC lifted its holdings in shares of Emergent BioSolutions by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company’s stock valued at $4,861,000 after buying an additional 25,776 shares during the last quarter. Finally, Wellington Management Group LLP lifted its stake in Emergent BioSolutions by 19.6% in the third quarter. Wellington Management Group LLP now owns 136,289 shares of the biopharmaceutical company’s stock valued at $1,138,000 after acquiring an additional 22,295 shares during the last quarter. Institutional investors and hedge funds own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.